CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy

D. Ennishi, K. Takeuchi, M. Yokoyama, H. Asai, Y. Mishima, Y. Terui, S. Takahashi, H. Komatsu, K. Ikeda, M. Yamaguchi, R. Suzuki, M. Tanimoto, K. Hatake

Research output: Contribution to journalArticlepeer-review

78 Citations (Scopus)

Fingerprint

Dive into the research topics of 'CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences